早期β受体阻滞剂暴露与中重度创伤性脑损伤危重患者功能结局的关联:TRACK-TBI研究
本研究为回顾性队列研究,纳入TRACK-TBI研究中18家美国一级创伤中心ICU收治的≥17岁、格拉斯哥昏迷评分<13分的中重度钝性TBI患者450例,其中57例(13%)在ICU最初7天内接受β受体阻滞剂(BB+组)。BB+组平均年龄更大、更可能有伤前β受体阻滞剂使用史和高血压病史。多变量回归显示BB+组与BB-组6个月GOSE评分升高的比值比无差异(OR 0.86,95%CI 0.48-1.53),β受体阻滞剂暴露与各项次要结局均无关联。作者指出结论受限于总剂量较低。
要点
- 450例中重度TBI患者中57例(13%)在ICU最初7天内接受β受体阻滞剂,BB+组平均年龄更大、更常有伤前β受体阻滞剂使用史和高血压病史。
- BB+组用药构成:34例(60%)仅用美托洛尔,19例(33%)仅用普萘洛尔,3例(5%)两者联用,1例(2%)仅用阿替洛尔。
- 多变量回归显示BB+组与BB-组6个月GOSE评分升高的比值比无差异(OR 0.86,95%CI 0.48-1.53)。
- β受体阻滞剂暴露与住院时长、院内死亡率、6个月和12个月死亡率、12个月GOSE评分及6个月和12个月残疾、幸福感、生活质量、生活满意度等次要结局均无关联。
- 作者认为结论受限于总剂量较低(与既往研究相比),且β受体阻滞剂的剂量和给药时机差异很大。
适用人群与场景
- ≥17岁、格拉斯哥昏迷评分<13分、钝性TBI后入住ICU的中重度TBI患者,来自TRACK-TBI研究中18家美国一级创伤中心。
诊断标准与关键阈值
- 中重度TBI定义为格拉斯哥昏迷评分<13分。
- 主要暴露为ICU最初7天内接受β受体阻滞剂。
研究设计与关键结果
- 研究类型:回顾性队列研究,纳入TRACK-TBI研究中18家美国一级创伤中心ICU的450例中重度TBI患者,57例(13%)接受早期β受体阻滞剂(BB+组)。
- BB+组用药:34例(60%)仅美托洛尔,19例(33%)仅普萘洛尔,3例(5%)两者联用,1例(2%)仅阿替洛尔。
- 主要终点:多变量回归显示BB+组与BB-组6个月GOSE评分升高的比值比无差异(OR 0.86,95%CI 0.48-1.53)。
- 次要终点:β受体阻滞剂暴露与住院时长、院内死亡率、6个月和12个月死亡率、12个月GOSE评分及6个月和12个月残疾、幸福感、生活质量、生活满意度均无关联。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:作者指出结论受限于总剂量较低(与既往研究相比),且β受体阻滞剂的剂量和给药时机差异很大。
对床旁实践的改变
- 作者认为,尽管6个月GOSE评分无显著差异,但受限于总剂量较低,尚不能据此得出β受体阻滞剂对中重度TBI功能结局有或无影响的结论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to 1) describe patterns of beta-blocker utilization among critically ill patients following moderate-severe traumatic brain injury (TBI) and 2) examine the association of early beta-blocker exposure with functional and clinical outcomes following injury.
DESIGN: Retrospective cohort study.
SETTING: ICUs at 18 level I, U.S. trauma centers in the Transforming Clinical Research and Knowledge in TBI (TRACK-TBI) study.
PATIENTS: Greater than or equal to 17 years enrolled in the TRACK-TBI study with moderate-severe TBI (Glasgow Coma Scale of <13) were admitted to the ICU after a blunt TBI.
INTERVENTIONS: None.
MEASUREMENTS: Primary exposure was a beta blocker during the first 7 days in the ICU, with a primary outcome of 6-month Glasgow Outcome Scale-Extended (GOSE). Secondary outcomes included: length of hospital stay, in-hospital mortality, 6-month and 12-month mortality, 12-month GOSE score, and 6-month and 12-month measures of disability, well-being, quality of life, and life satisfaction.
MAIN RESULTS: Of the 450 eligible participants, 57 (13%) received early beta blockers (BB+ group). The BB+ group was on average older, more likely to be on a preinjury beta blocker, and more likely to have a history of hypertension. In the BB+ group, 34 participants (60%) received metoprolol only, 19 participants (33%) received propranolol only, 3 participants (5%) received both, and 1 participant (2%) received atenolol only. In multivariable regression, there was no difference in the odds of a higher GOSE score at 6 months between the BB+ group and BB- group (odds ratio = 0.86; 95% CI, 0.48-1.53). There was no association between BB exposure and secondary outcomes.
CONCLUSIONS: About one-sixth of subjects in our study received early beta blockers, and within this group, dose, and timing of beta-blocker administration varied substantially. No significant differences in GOSE score at 6 months were demonstrated, although our ability to draw conclusions is limited by overall low total doses administered compared with prior studies.
参考来源
- Kelly-Hedrick M, Liu SY, Temkin N, et al. Association of Early Beta-Blocker Exposure and Functional Outcomes in Critically Ill Patients With Moderate to Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study. Crit Care Explor. 2023. PMID: 37693305. doi:10.1097/CCE.0000000000000958
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。